Li YY - Search Results

1

Hepatocytic ballooning in non-alcoholic steatohepatitis: Dilemmas and future directions.

Li YY, Zheng TL, Xiao SY, Wang P, Yang WJ, Jiang LL, Chen LL, Sha JC, Jin Y, Chen SD, Byrne CD, Targher G, Li JM, Zheng MH. Li YY, et al. Among authors: li jm. Liver Int. 2023 Jun;43(6):1170-1182. doi: 10.1111/liv.15571. Epub 2023 Apr 5. Liver Int. 2023. PMID: 37017559 Review.

2

Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.

Zhou YJ, Ye FZ, Li YY, Pan XY, Chen YX, Wu XX, Xiong JJ, Liu WY, Xu SH, Chen YP, Zheng MH. Zhou YJ, et al. Among authors: li yy. United European Gastroenterol J. 2019 Oct;7(8):1124-1134. doi: 10.1177/2050640619868352. Epub 2019 Jul 30. United European Gastroenterol J. 2019. PMID: 31662869 Free PMC article.

3

Increased CDK4 protein expression predicts a poor prognosis in mucosal melanoma associated with the p16^INK4a-CDK4-pRb pathway.

Wang F, Chen G, Quinn MJ, Chen S, Ji X, Shentu Y, Li Y. Wang F, et al. Int J Clin Exp Pathol. 2019 Aug 1;12(8):2819-2825. eCollection 2019. Int J Clin Exp Pathol. 2019. PMID: 31934118 Free PMC article.

4

Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.

Gao F, Huang JF, Zheng KI, Pan XY, Ma HL, Liu WY, Byrne CD, Targher G, Li YY, Chen YP, Chan WK, Zheng MH. Gao F, et al. Among authors: li yy. J Gastroenterol Hepatol. 2020 Oct;35(10):1804-1812. doi: 10.1111/jgh.15055. Epub 2020 Apr 28. J Gastroenterol Hepatol. 2020. PMID: 32246876

5

Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease.

Zhu SH, Zheng KI, Hu DS, Gao F, Rios RS, Li G, Li YY, Byrne CD, Targher G, Chen YP, Zheng MH. Zhu SH, et al. Among authors: li yy, li g. Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):430-435. doi: 10.1097/MEG.0000000000001746. Eur J Gastroenterol Hepatol. 2021. PMID: 32398489

6

Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD.

Qiao ZP, Zheng KI, Zhu PW, Gao F, Ma HL, Li G, Li YY, Targher G, Byrne CD, Zheng MH. Qiao ZP, et al. Among authors: li yy, li g. Nutr Metab Cardiovasc Dis. 2020 Sep 24;30(10):1820-1825. doi: 10.1016/j.numecd.2020.05.017. Epub 2020 Jun 2. Nutr Metab Cardiovasc Dis. 2020. PMID: 32636124

7

FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease.

Gao F, Zheng KI, Zhu PW, Li YY, Ma HL, Li G, Tang LJ, Rios RS, Liu WY, Pan XY, Targher G, Byrne CD, Chen YP, Zheng MH. Gao F, et al. Among authors: li yy, li g. Br J Nutr. 2021 Sep 28;126(6):813-824. doi: 10.1017/S0007114520004559. Epub 2020 Nov 17. Br J Nutr. 2021. PMID: 33198849

8

Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD.

Feng G, Zheng KI, Li YY, Rios RS, Zhu PW, Pan XY, Li G, Ma HL, Tang LJ, Byrne CD, Targher G, He N, Mi M, Chen YP, Zheng MH. Feng G, et al. Among authors: li yy, li g. J Hepatobiliary Pancreat Sci. 2021 Jul;28(7):593-603. doi: 10.1002/jhbp.972. Epub 2021 May 12. J Hepatobiliary Pancreat Sci. 2021. PMID: 33908180 Clinical Trial.

9

LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.

Wang ZH, Zheng KI, Wang XD, Qiao J, Li YY, Zhang L, Zheng MH, Wu J. Wang ZH, et al. Among authors: li yy. Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):452-459. doi: 10.1016/j.hbpd.2021.05.008. Epub 2021 Jun 25. Hepatobiliary Pancreat Dis Int. 2021. PMID: 34256994

10

Global multi-stakeholder endorsement of the MAFLD definition.

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,451 results

Search Page